Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well tandutinib works in treating patients with
progressive prostate cancer and bone metastases.